Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan
With the introduction of new treatments and emerging evidence supporting cardio-renal protective effects in people with CKD and T2D, notable changes in baseline treatment were observed in the medication-initiator cohort characteristics. These findings suggest the earlier use of cardio-renal protective medications in the course of T2D.
Authors
- Naoki Kashihara (ORCID: https://orcid.org/0000-0002-9487-984X)
- Catherine B. Johannes (ORCID: https://orcid.org/0000-0002-0586-9886)
- Suguru Okami (ORCID: https://orcid.org/0000-0003-4402-0209)
- David Vizcaya (ORCID: https://orcid.org/0000-0003-0248-7636)
- Hiroshi Kanegae (ORCID: https://orcid.org/0000-0001-5075-3594)
- Yuichiro Yano (ORCID: https://orcid.org/0000-0002-2565-7290)
- Satoshi Yamashita (ORCID: https://orcid.org/0000-0002-8609-5797)
- Nikolaus G. Oberprieler
- Csaba Pal Kovesdy (ORCID: https://orcid.org/0000-0002-8204-911X)
- Kanae Yoshikawa‐Ryan
Institutions
- Shiga University of Medical Science (JP)
- University of Tennessee Health Science Center (US)
- Kawasaki Medical School (JP)
- Juntendo University (JP)
- Genki Plaza Medical Center for Health Care (JP)
- RTI Health Solutions (US)
- Bayer (Japan) (JP)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1111/dom.16394
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29